Violet Therapeutics is a pre-clinical stage company leveraging first-in-class platforms to identify, map, and mine the cellular connectome.
Violet Therapeutics has raised $4.8M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
Violet Therapeutics's investors include UTEC - The University of Tokyo Edge Capital Partners, Dementia Discovery Fund, Ono Venture Investment, Mass General Brigham Ventures, Lifespan Vision Ventures.
Violet Therapeutics is headquartered in Cambridge, United States.
Violet Therapeutics is a pre-clinical stage company leveraging first-in-class platforms to identify, map, and mine the cellular connectome.
Violet Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Violet Therapeutics — Funding & Investors." VCBacked, May 13, 2026, https://www.vcbacked.co/company/violet-therapeutics. Accessed July 20, 2026.
VCBacked. (2026). Violet Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/violet-therapeutics
{{cite web |title=Violet Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/violet-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated